Cargando…
Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy
Immune checkpoint inhibitors (ICIs) significantly improve the survival of patients with non-small-cell lung cancer (NSCLC), but only some patients obtain clinical benefits. Predictive biomarkers for ICIs can accurately identify people who will benefit from immunotherapy. Lipid metabolism signaling p...
Autores principales: | Cheng, Tianli, Zhang, Jing, Liu, Danni, Lai, Guorong, Wen, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317604/ https://www.ncbi.nlm.nih.gov/pubmed/34335679 http://dx.doi.org/10.3389/fgene.2021.646362 |
Ejemplares similares
-
Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung Cancer
por: Gu, Xinpei, et al.
Publicado: (2022) -
Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Wang, Helin, et al.
Publicado: (2022) -
Identification of NAD(+) Metabolism-Derived Gene Signatures in Ovarian Cancer Prognosis and Immunotherapy
por: Lin, Liang, et al.
Publicado: (2022) -
Application of an angiogenesis-related genes risk model in lung adenocarcinoma prognosis and immunotherapy
por: Wang, Jinsong, et al.
Publicado: (2023) -
Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma
por: Zhou, Xincheng, et al.
Publicado: (2022)